(News Bulletin 247) – Invest Securities maintains its buy rating on OSE Immunotherapeutics, with an unchanged price target of 8.2 euros, after the company announced last week that it had obtained a loan for an amount of 1.5mE from Bpifrance to accelerate the development of a companion diagnostic test associated with the therapeutic vaccine Tedopi in lung cancer.
‘This amount should cover all the development costs of the test whose HLA-A2 methods have already been identified’, estimates the analyst who indicates that the launch of the Ph III evaluating Tedopi in lung cancer is expected before the end of the year 2023.
‘In line with its business model, OSE Immuno plans to enter into an agreement with an industrial partner to partially bear the costs of the Ph III. The financial visibility to date extends to Q2 2024, which implies a strengthening in the short term”, concludes Invest.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
